Cellectis wins FDA RMAT designation for allogeneic CAR-T lasme-cel
Cellectis has received Regenerative Medicine Advanced Therapy (RMAT) designation from the US Food and Drug Administration for lasmecabtagene timgedleucel (lasme-cel), its allogeneic CD22-targeting CAR-T cell therapy candidate, in relapsed or refractory B-cell acute lymphoblastic leukaemia (r/r B-ALL). The designation, granted on 9 June 2026, is supported by Phase 1 data from the BALLI-01 trial, which the company says demonstrated promising efficacy alongside a manageable safety profile.
Cellectis describes lasme-cel as the first allogeneic CAR-T therapy to enter a pivotal trial in this indication. The pivotal Phase 2 arm of BALLI-01 is currently open for enrolment (NCT04150497). Final Phase 1 data from the study are scheduled to be presented in an oral session at the 2026 European Haematology Association Congress on 13 June, delivered by Nitin Jain, Professor of Medicine in the Department of Leukaemia at MD Anderson Cancer Center.
What RMAT means in practice
RMAT designation, established under the 21st Century Cures Act, is reserved for regenerative medicines that show preliminary clinical evidence of addressing serious conditions with unmet need. Like Breakthrough Therapy designation, it unlocks more intensive FDA engagement — including early dialogue on trial design and surrogate endpoints — and makes a product eligible for priority review and rolling submission. Importantly, the designation does not guarantee approval, and Cellectis's own cautionary language acknowledges it can be withdrawn if the product no longer meets the criteria.
Co-founder and chief executive André Choulika said the designation "strengthens our dialogue with the FDA as we advance lasme-cel through its pivotal programme," framing the milestone as validation of the clinical case for off-the-shelf CAR-T options in a patient population that, he noted, "cannot wait" for autologous manufacturing timelines.
Competitive landscape
The allogeneic CAR-T space has had a turbulent few years. Several early programmes from competitors, including those targeting CD19, encountered durability and engraftment challenges in pivotal settings, leading to clinical holds and, in some cases, programme terminations. Cellectis's shift to CD22 targeting is a deliberate differentiation — CD22 is less commonly targeted than CD19 in B-ALL, and dual-antigen relapse following CD19-directed therapy is a well-characterised clinical problem that lasme-cel is positioned to address.
The broader r/r B-ALL treatment landscape includes autologous CD19-directed CAR-T products with established approvals, as well as blinatumomab and inotuzumab ozogamicin. For patients who relapse after or are ineligible for those options, the unmet need remains significant. An allogeneic, off-the-shelf product that could be administered rapidly without the delays inherent to patient-specific manufacturing would represent a meaningful logistical advantage — if the pivotal data support the efficacy and durability seen at Phase 1.
Cellectis's in-house end-to-end manufacturing capability is a structural differentiator in this context, reducing reliance on contract development and manufacturing organisations and giving the company direct control over batch consistency and supply chain — a recurring concern in cell therapy commercialisation. How that scales to pivotal-trial and, eventually, commercial volumes will be a key question for investors watching the BALLI-01 readout.
The EHA presentation on 13 June will be the first detailed public look at the complete Phase 1 dataset and is likely to set the tone for investor sentiment ahead of pivotal enrolment milestones later in the year.